Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Outlook Therapeutics Inc

OTLK ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.76

▼ -14.90%

Market Cap $141.44M · Vol 5.77M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$141.44M

Micro Cap

Div Yield

N/A

EPS Growth

+72.44%

YoY

RSI (14)

36.81

Momentum

Beta

0.73

vs Market

52W High

$3.37

77.55% below

52W Low

$0.16

366.63% above

Volume

5.77M

Avg 2.21M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

85.03%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Outlook Therapeutics Inc (OTLK) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OTLK pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-25.84%

-56.28%

+224.36%

+54.37%

YTD

-52.13%

-68.87%

-97.56%

-98.42%

Financials & Valuation

TTM · Annual

Total Revenue	$1.41M
Net Income	$-62,424,860.00
Revenue Growth (YoY)	N/A
Gross Margin	4.05%
Operating Margin	-4,744.25%
Net Profit Margin	-4,416.22%
ROE	N/A
ROA · ROIC	-269.90% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	26.09
P/B	N/A
P/FCF	N/A
EPS Growth	+72.44%
Outstanding Shares	187.00M

Technical Indicators

50-Day SMA	$1.28
200-Day SMA	$0.92
RSI (14)	36.81
Beta	0.73
52-Week High	$3.37
52-Week Low	$0.16

Volume Today	5.77M
Avg Daily Volume (30D)	2.21M
Relative Volume	2.62x
Volatility (10D)	156.47
Volatility (30D)	151.38
Free Float	85.03%

Analyst Consensus

BUY

Current Price $0.76

Mean Target $5.40

52W Low$0.16 52W High$3.37

Current

Target

$0.16 $3.37

Current Analyst target

+613.91% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00469JRM1

ISINUS69012T3059

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 14, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.